Medical/Pharmaceuticals

Transcenta Presents First Data from Phase 1 Study of pH-Dependent PDL1 Antibody MSB2311 in Patients with Pre-treated Advanced Solid Tumors and Select Hematological Malignancies

SUZHOU, China, May 27, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery,development and manufacturing of antibody-based therapeutics, announced today results reported for the first time from a Phase 1...

2020-05-27 23:00 1231

United Imaging uMR OMEGA Cleared by FDA, Available in U.S. Market

HOUSTON, May 26, 2020 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced U.S. Food & Drug Administration (FDA) clearance of the uMR OMEGATM magnetic resonance imaging (MRI) scanner. The uMR OMEGA offers the world's first ultra-wide 75...

2020-05-26 20:00 1537

Mayne Pharma launches BAC 300 capsules in the United States

ADELAIDE, Australia, May 22, 2020 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of butalbital acetaminophen and caffeine (BAC) capsule 50mg/300mg/40mg inthe United States. Mayne Pharma received approval from the US Food and Drug Administration for its Abb...

2020-05-22 13:44 5649

Nippon Express (UK) Receives WDA and GDP Certification for Company Warehouse near London Heathrow Airport

TOKYO, May 22, 2020 /PRNewswire/ -- Nippon Express (UK) Co., Ltd. (hereinafter, "NEUK"), a local subsidiary of Nippon Express Co., Ltd. based inTokyo, has been officially granted Wholesale Distribution Authorisation (WDA) and Good Distribution Practice (GDP) certification for its warehouse near L...

2020-05-22 13:00 1492

GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio

LONDON and SONGDO, South Korea, May 21, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung Biologics (207940.KS) have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK's innovative biopharmaceutical therapies. Under the terms of th...

2020-05-22 07:11 6464

FibroGenesis Reports COVID-19 Breakthrough Using Fibroblast Cell Therapy (Pre-Clinical Trial Phase)

PneumoBlast™ Reduces Pathology and Lung Fluid Accumulation in Model of COVID-19 HOUSTON, May 21, 2020 /PRNewswire/ -- FibroGenesis announced today significant efficacy of its PneumoBlast™ product in an animal model of lung inflammation which resembles COVID-19.  Mice immune systems were stimulate...

2020-05-21 22:03 2325

I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7™ in Glioblastoma Multiforme

SHANGHAI, GAITHERSBURG, Md. and SEOUL, South Korea, May 21, 2020 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medi...

2020-05-21 20:00 5856

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

MELBOURNE, Austrilia and SAN FRANCISCO, May 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting....

2020-05-21 08:58 6154

China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction

BEIJING, May 20, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today declared that Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan"), China Biolog...

2020-05-21 04:45 11512

China Biologic Reports Financial Results for the First Quarter of 2020

BEIJING, May 20, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the first quarter of 2020. First Quarter ...

2020-05-21 04:30 10678

Macrogen Approved for Export of its COVID-19 Test Kit

SEOUL, South Korea, May 20, 2020 /PRNewswire/ -- The Korean biotech company Macrogen (CEO Sukang Lee) (KOSDAQ: 038290), announced that it obtained export approval for COVID-19 test kit 'AxenTM COVID-19 RT' from the Ministry of Food and Drug Safety (MFDS) on the 18th. ...

2020-05-20 21:00 1920

I-Mab Expands Global Presence with New Hong Kong Office

SHANGHAI and ROCKVILLE, Md., May 20, 2020 /PRNewswire/ -- I-Mab (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly ...

2020-05-20 16:00 7839

VSMS ECG Patch receives US FDA 'Emergency Use Authorisation' for patients being treated for COVID-19

* Patch now authorised in the USA for emergency use for patients undergoing treatment for COVID-19 * Patch entitled for reimbursement under US CPT code scheme – adds to GMV's growing revenue profile * Large addressable market for G Medical - ~1.5m confirmed cases of COVID-19 recorded in the...

2020-05-20 10:50 1226

Samsung Biologics Expands Business Continuity Excellence with Additional ISO22301 Certification

SONGDO, South Korea, May 19, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced it has attained ISO22301 certification for additional business operations, demonstrating its unsurpassed commitment to ensuring client satisfaction and operational excellence through its world-class business...

2020-05-20 07:11 1864

VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

AUSTIN, Texas, May 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers a...

2020-05-20 04:01 8492

WuXi Advanced Therapies Launches New Closed Process CAR-T Cell Therapy Platform

PHILADELPHIA, May 18, 2020 /PRNewswire/ -- WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advanced therapies industry, announced today the expansion of its service capabilities to offer a fully int...

2020-05-18 21:00 1997

I Peace, Inc. Begins Clinical-Grade Induced Pluripotent Stem Cells Custom Manufacturing Service

PALO ALTO, Calif., May 15, 2020 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe ), aPalo Alto-based biotech start-up focusing on Nobel Prize-wining technology "induced pluripotent stem cell (iPSC)" began manufacturing clinical-grade iPSCs. We are now officially taking orders for custom manufacturi...

2020-05-16 01:00 2665

China Pharma Holdings, Inc. Reports First Quarter 2020 Financial Results

HAIKOU CITY, China, May 15, 2020 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the qua...

2020-05-15 18:30 11776

SciMount announces FDA approval of SMP-100's IND application for the treatment of Irritable Bowel Syndrome

CHENGDU, China, May 13, 2020 /PRNewswire/ -- SciMount Pharmatech, Co. Ltd., a wholly-owned subsidiary ofXiling Lab, announces today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for SMP-100 for the treatment of Irritable Bowel Synd...

2020-05-14 18:00 1217

First Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors

SHANGHAI and ROCKVILLE, Md., May 13, 2020 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announ...

2020-05-13 20:00 5352
1 ... 201202203204205206207 ... 214

Week's Top Stories